Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunisation, asymptomatic infection, herd immunity and the new variants of COVID 19

View ORCID ProfileAlastair Grant, View ORCID ProfilePaul R Hunter
doi: https://doi.org/10.1101/2021.01.16.21249946
Alastair Grant
1School of Environmental Science, University of East Anglia, Norwich, NR4 7TJ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alastair Grant
  • For correspondence: A.Grant@uea.ac.uk
Paul R Hunter
2The Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul R Hunter
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives Is “herd immunity” to COVID-19 a realistic outcome of any immunisation programme with the two main vaccines currently licenced in the UK (Pfizer vaccine BNT162b2 and Astra Zeneca/Oxford vaccine ChAdOx1-S)? More formally, can these vaccines achieve a sufficient level of population immunity to reduce R, the reproduction number of the infection, to below one in the absence of any non-pharmaceutical interventions?

Design The study uses simple mathematical models of the transmission of COVID-19 infection from primary to secondary cases parameterised using data on virus transmission and vaccine efficacy from the literature and the regulatory approval process for the vaccines.

Results In the regulatory approval documents, the efficacy of the Pfizer vaccine is estimated at 0.948 (that for the Moderna vaccine is similar). Efficacy for the Oxford vaccine against primary symptomatic illness is estimated as 0.704, based on pooling of data from two dose regimes. For values of R0 similar to those reported during the first months of the pandemic, the simplest analysis implies that reducing the value of R below 1 would require 69% and 93% of the population to be vaccinated with the Pfizer and Oxford vaccine respectively (or achieve a comparable level of immunity through natural infection). However, the new variant of COVID-19 (Lineage B.1.1.7, named Variant of Concern VOC-202012/01) is reported to have an R-value 1.56 (0.92 to 2.28) times higher than the original strain. Vaccinating the entire population with the Oxford vaccine would only reduce the R value to 1.325 while the Pfizer vaccine would require 82% of the population to be vaccinated to control the spread of the new variant.

The Oxford vaccine reduces the incidence of serious illness to a greater extent than it reduces symptomatic illness. But its efficacy against the incidence of asymptomatic infections is lower, reducing its efficacy against all infection from 0.704 to 0.525 for the pooled data. Although asymptomatics are less infectious, including them in our calculations still raises R values by 20% or more, from 1.33 to 1.6 for the new variant with 100% vaccination. Neither vaccine is licenced for use in children, and when this is taken into account, this R value rises by a further 37% to 2.2 if the whole adult population is vaccinated. Even the more effective mRNA vaccines may allow the pandemic to persist via transmission amongst children, as current authorisations only allow their use on adults. In the absence of vaccination, R will reduce to 1 when 89% of the population has acquired immunity as a result of previous infection with COVID-19.

Conclusions All currently licensed vaccines provide substantial protection against serious illness to vaccinated individuals themselves. But the Oxford vaccine appears to have relatively low efficacy against asymptomatic infections. Although no comparable data from human trials are available for the mRNA vaccines, non-human primate studies suggest they are better at preventing nasal shedding and so transmission. Herd immunity to COVID-19 will be very difficult to achieve, especially so for the less effective vaccine. The possibility of transmission from vaccinated but infected individuals to vulnerable unvaccinated individuals is of serious concern. There is a strong case for preferring the more effective mRNA vaccines for health and social care workers and those who have contact with large numbers of vulnerable others.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

modelling study only

Funding Statement

Professor Hunter was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emergency Preparedness and Response at Kings College London in partnership with Public Health England (PHE) and collaboration with the University of East Anglia. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, UEA, the Department of Health or PHE.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Study involves modelling based on public domain data. No ethical approval required

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Declarations

    Conflict of interest

  • The authors declare that we have no conflict of interest.

  • Funding Professor Hunter was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emergency Preparedness and Response at King’s College London in partnership with Public Health England (PHE) and collaboration with the University of East Anglia. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, UEA, the Department of Health or PHE.

Data Availability

Data are taken from published papers and sources. All these are cited in the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 20, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunisation, asymptomatic infection, herd immunity and the new variants of COVID 19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunisation, asymptomatic infection, herd immunity and the new variants of COVID 19
Alastair Grant, Paul R Hunter
medRxiv 2021.01.16.21249946; doi: https://doi.org/10.1101/2021.01.16.21249946
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Immunisation, asymptomatic infection, herd immunity and the new variants of COVID 19
Alastair Grant, Paul R Hunter
medRxiv 2021.01.16.21249946; doi: https://doi.org/10.1101/2021.01.16.21249946

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (243)
  • Allergy and Immunology (525)
  • Anesthesia (125)
  • Cardiovascular Medicine (1435)
  • Dentistry and Oral Medicine (220)
  • Dermatology (158)
  • Emergency Medicine (293)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (589)
  • Epidemiology (10335)
  • Forensic Medicine (6)
  • Gastroenterology (533)
  • Genetic and Genomic Medicine (2656)
  • Geriatric Medicine (255)
  • Health Economics (499)
  • Health Informatics (1744)
  • Health Policy (791)
  • Health Systems and Quality Improvement (682)
  • Hematology (269)
  • HIV/AIDS (571)
  • Infectious Diseases (except HIV/AIDS) (12119)
  • Intensive Care and Critical Care Medicine (650)
  • Medical Education (276)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2484)
  • Nursing (145)
  • Nutrition (381)
  • Obstetrics and Gynecology (497)
  • Occupational and Environmental Health (569)
  • Oncology (1335)
  • Ophthalmology (403)
  • Orthopedics (153)
  • Otolaryngology (239)
  • Pain Medicine (172)
  • Palliative Medicine (51)
  • Pathology (345)
  • Pediatrics (786)
  • Pharmacology and Therapeutics (334)
  • Primary Care Research (297)
  • Psychiatry and Clinical Psychology (2422)
  • Public and Global Health (5032)
  • Radiology and Imaging (902)
  • Rehabilitation Medicine and Physical Therapy (536)
  • Respiratory Medicine (688)
  • Rheumatology (309)
  • Sexual and Reproductive Health (257)
  • Sports Medicine (246)
  • Surgery (300)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)